![Page 1: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/1.jpg)
1
CASE #2
Sam Shahpar, MD
Instructor, Feinberg School of Medicine at Northwestern University
Attending Physician, Cancer Rehabilitation Program at RIC
![Page 2: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/2.jpg)
2
DISCLOSURE
I have NO RELEVANT financial disclosures.
![Page 3: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/3.jpg)
3
L lung nodule identify incidentally in CT imaging
Initially needle biopsy was non-diagnostic but PET imaging revealed enlarged nodule and smaller R upper nodule
Underwent mediastinoscopy, B VATS with R upper lobe nodule/wedge resection and L upper lobe nodule resection/segmentectomy• Pathology revealed grade 2-3 L lung adenocarcinoma with neg
margins and R lung adenocarcinoma with positive margins (Requiring R upper lobectomy subsequently)
BACKGROUND
![Page 4: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/4.jpg)
4
Staging work-up notable for brain lesion c/w meningioma v. brain mets but no other systemic metastases
Thought to have 2 separate lung primary malignancies and initiated on adjuvant chemotherapy with cisplatin, pemetrexed with course notable for severe debilitating neuropathy requiring transition to carboplatin for last cycle
BACKGROUND
![Page 5: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/5.jpg)
5
Neuropathy started after 1st cycle of chemotherapy with numbness/tingling and burning of feet but soon progressed to hands/wrist
Associated weakness in hand grip and impaired balance, falling up to 4x/week
Lab work and EMG/NCS was WNL
BACKGROUND
![Page 6: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/6.jpg)
6
Seen by Physiatrist on Oct 2013 (started chemotherapy in April 2012 ) and reported decreased sensation of vaginal, perineal, and rectal areas
Had been present since initial neuropathy symptoms but had not told any other healthcare providers
Associated urinary incontinence managed with timed toileting and decreased bowel sensations
BACKGROUND
![Page 7: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/7.jpg)
7
Lives in home with husband with 1 daughter with cerebral palsy
Acts as primary caregiver to daughter
On disability due to lung cancer
Sister passed away from Lung cancer during the week she initiated chemotherapy (had same Oncologist)
BACKGROUND
![Page 8: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/8.jpg)
8
What would be your be the recommended treatment plan?
1. Refer to Neurologist and/or another specialist
2. Refer to physical and/or occupational therapy
3. Initiate medication
4. All of the above
DECISIONS, DECISIONS
![Page 9: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/9.jpg)
9
9/2/112 A Neural Interface for Artificial Limbs: Targeted Muscle Reinnervation
![Page 10: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/10.jpg)
10
Medications• Gabapentin 300mg QID• Nortriptyline 25mg HS• Hydrocodone/Acetaminophen 5-325mg q6hr PRN• Multivitamin daily
BACKGROUND
![Page 11: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/11.jpg)
11
What changes, if any, would you make to medication regimen?
1. No changes
2. Increase Gabapentin
3. Increase Nortriptyline
4. Increase Opioids
5. Trial New Medication
DECISIONS, DECISIONS
![Page 12: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/12.jpg)
12
9/2/112 A Neural Interface for Artificial Limbs: Targeted Muscle Reinnervation
![Page 13: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/13.jpg)
13
Moderate recommendation for treatment with duloxetine
• Tricyclic antidepressants, Gabapentin, Compounded Topical gel (baclofen 10 mg, amitriptyline 40 mg, and ketamine 20 mg)
May be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other treatment options
Further research on these agents is warranted
ASCO TREATMENT GUIDELINES
![Page 14: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/14.jpg)
14
Increase Gabapentin to 300/300/300/600mg • Patient hesitant to increase further due to possible
sedation/side effects
Further work-up with imaging for saddle anesthesia, bowel/bladder changes
Referred to intensive therapy program given significantly impaired function
INITIAL RECOMMENDATIONS
![Page 15: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/15.jpg)
15
Referral to Chronic Pain Program - enrolled in a Full day program
Includes M-F, 8 hours per day for 4 weeks
Team members include:• Physiatrist, Pain Psychologist, Occupational Therapists,
Physical Therapists, Relaxation Therapists, Nursing Education experts, Clinical Care Manager and Vocational Rehabilitation specialists
NEXT STEPS
![Page 16: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/16.jpg)
16
Medications• Gabapentin 600mg QID• Nortriptyline 25mg HS• Hydrocodone/Acetaminophen 5-325mg q6hr PRN• Multivitamin daily
START OF PAIN PROGRAM
![Page 17: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/17.jpg)
17
What changes, if any, would you make to medication regimen?
1. No changes
2. Increase Gabapentin
3. Increase Nortriptyline
4. Increase Opioids
5. Trial New Medication
DECISIONS, DECISIONS
![Page 18: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/18.jpg)
18
9/2/112 A Neural Interface for Artificial Limbs: Targeted Muscle Reinnervation
![Page 19: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/19.jpg)
19
Medications• Gabapentin 600mg QID• Nortriptyline 25mg HS• Hydrocodone/Acetaminophen 5-325mg q6hr PRN• Multivitamin daily
Increased Gabapentin to 800mg QID
START OF PAIN PROGRAM
![Page 20: 1 CASE #2 Sam Shahpar, MD Instructor, Feinberg School of Medicine at Northwestern University Attending Physician, Cancer Rehabilitation Program at RIC](https://reader036.vdocuments.us/reader036/viewer/2022070116/56649f4d5503460f94c6d3ba/html5/thumbnails/20.jpg)
20
No clear standard of care
Guidelines may help direct decision making
More research is needed
TAKE HOME POINTS